Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of the National Cancer Institute|May 18, 2022
The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic ProfilingKumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, et al.
Future Oncology (London, England)|July 27, 2021
Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencingSally E Trabucco, Ethan S Sokol, Sophia L Maund, et al.
Targeted Oncology|April 13, 2024
The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic ProfilingHiroyuki Yamamoto, Hiroyuki Arai, Ritsuko Oikawa, et al.
JCO Precision Oncology|August 8, 2024
Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable AlterationsHiroyuki Takeda, Hiroyuki Yamamoto, Ritsuko Oikawa, et al.
The Lancet. Digital Health|May 26, 2023
Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysisSmruthy Sivakumar, Jessica K Lee, Jay A Moore, et al.
Cancer Discovery|April 16, 2023
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic TransformationSmruthy Sivakumar, Jay A Moore, Meagan Montesion, et al.
JCO Precision Oncology|September 3, 2021
Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or CholangiocarcinomaKarthikeyan Murugesan, Radwa Sharaf, Meagan Montesion, et al.
Cancer Research Communications|August 8, 2024
Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic FeaturesN Ari Wijetunga, Kathryn H Gessner, Krishna Kanchi, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor ResponseJay A Moore, Kuei-Ting Chen, Russell Madison, et al.
Cancer Discovery|October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor ResponseMeagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
Pageof 1